Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls

aDepartment of Oncology, Queen's University

bDivision of Hematology and Oncology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario

cDepartment of Public Health Sciences

dDivision of Cancer Care and Epidemiology, Queen's University, Kingston, Canada

Correspondence to Dr Bishal Gyawali, 10 Stuart Street, Cancer Research Institute, Queen's University, Kingston, Canada. Tel: +1 613 533 6000 ext 78509; e-mail: [email protected]

Comments (0)

No login
gif